ArticleJMA journal2025
Incidence of Bloodstream Infections in Pediatric Patients with Cancer during Febrile Neutropenia: A Retrospective Study.
Article in JMA journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Situation and questions regarding the practice of blood cultures in paediatric patients: an opinion paper.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bloodstream infections (BSIs) are a major concern in pediatric patients with cancer, especially during episodes of febrile neutropenia (FN). In this study, we aimed to evaluate the incidence of BSI across various pediatric malignancies and identify cancer subtypes associated with a heightened risk of BSI. Methods: This single-center, retrospective cohort study analyzed the electronic medical records of pediatric patients with cancer treated between April 2012 and March 2023. Eligible patients included those diagnosed with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), lymphoma, brain tumors, and solid tumors. For each chemotherapy course, we assessed BSI incidence and FN episodes. Results: This study included 152 pediatric patients who underwent 829 chemotherapy courses. The cohort comprised 21 patients with AML, 52 with ALL, 10 with lymphoma, 26 with brain tumors, and 43 with solid tumors. Compared to other cancer types, the AML group exhibited the highest proportion of BSI across all chemotherapy courses (17% vs. 4%-7%). During FN episodes, the AML cohort had a significantly higher BSI incidence (22%) than other groups (7%-13%). Notably, chemotherapy courses involving high-dose cytarabine (HD-CA) had a substantially higher BSI incidence (30%) among the patients with AML than courses without HD-CA (2%). Conclusions: Patients with AML have the highest risk of BSIs in pediatric malignancies, particularly during FN episodes. In addition, our findings highlight an association between BSIs and HD-CA use in patients with AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.